NR4A1 and breast cancer: POLARIS (NCT03280303), a prospective, observational, multicenter, cohort study, evaluated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) receiving palbociclib + endocrine therapy (ET) in routine care.